The study of prognostic significance of CA 15-3 in breast cancer
DOI:
https://doi.org/10.18203/2349-2902.isj20180356Keywords:
Breast cancer, CA 15-3, Follow-up, Metastasis, Prognostic markerAbstract
Background: Cancer Antigen 15-3 (CA 15-3) is a tumour-associated antigen used as serum marker for breast cancer surveillance in patients and for monitoring the response to treatment. Aim of this study was to prospectively evaluate CA 15-3 as a prognostic factor in early detection of breast cancer relapse, recurrence and early detection of distant metastasis as well as to analyse the statistical correlation between CA 15-3 levels and clinical-pathological parameters including tumour size, lymph node, histological type, grading, hormonal receptors.
Methods: Sera of 85 women with breast carcinoma obtained pre-treatment, post-treatment and follow-up at 6 months were assayed for CA 15-3 by solid phase enzyme-linked immunosorbent assay (ELISA).
Results: Author founds that the mean serum CA 15-3 levels in patients before treatment were significantly higher (50.59U/ml) compared with those of CA 15-3 after treatment (24.07U/ml) and follow-up at 6 months (21.07U/ml). Author also found that elevated pre-treatment serum levels of CA 15-3 were significantly correlated with poor prognosis of patients. In particular, among 16/85 patients (18.8%) that displayed over cut-off (>24.95U/ml) pre-treatment levels of CA 15-3, 2 patients (2.35%) developed recurrence,2 patients (2.35%) developed residual tumour, 2 patients (2.35%) developed advanced disease (metastases to distant sites) and 10 (11.76%) patients expired during and after study. Chi-square correlation analysis revealed that the presences of increased serum levels of CA 15-3 after treatment are significant risk factors for poor prognosis in patients.
Conclusions: Elevated pre-treatment concentrations of CA 15-3 may be a useful prognostic factor for cancer progression in patients.
Metrics
References
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136(5):E359-86.
FG Ebeling, P Stieber, M Untch, D Nagel, GE Konecny, UM Schmitt, et al. Serum CEA and CA15-3 as prognostic factor in primary breast cancer. Br J cancer. 2002;86:1217-22.
Lagow E, DeSouza MM, Carson DD. Mammalian reproductive tract mucins. Human Reproduction. 1999;15:280-92.
Agrawal B, Gendler SJ, Longenecker BM. The biological role of mucins in cellular interactions and immune regulation: Prospects for cancer immunotherapy. Molecular Medicine Today. 1998;4:397-403.
Brayman M, Thathiah A, Carson DD. MUC1: A multifunctional cell surface component of re-productive tissue epithelia. Reproductive Biol Endocrinol. 2004;2:1-9.
Parry S, Silverman HS, McDermott K, Willis A, Hollingsworth MA, Harris A. Identification of MUC1 proteolytic cleavage sites in vivo. Biochemical and biophysical research communications. 2001;283(3):715-20.
Molina R, Filella X, Alicarte J. prospective evaluation of CEA and CA15.3 in patients with locoregional breast cancer. Anticancer Res 2003;23:1035-41.
Canizares F, Sola J, Perez M. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumour Biol. 2001;22:273-81.
Berruti A, Tampellini M, Torta M. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer. 1994;30A:2082-4.
Kumpulainen EJ, Keskikuru RJ, Johansson RT. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat. 2002;76:95-102.
Zhang S, Hu Y, Qian H, Jiao S, Liu Z, Tao H et al. Asian Pacific J Cancer Prevention. 2013;14(6):3937-40.
Downloads
Published
How to Cite
Issue
Section
